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Alzheimer’s disease and other dementias are progressive,
debilitating conditions that affect millions of Americans,
their families, and federal and state governments. Total
payments for the care of people with Alzheimer’s and other
dementias was an estimated $226 billion in 2015, of which
nearly 70 percent was paid by Medicare and Medicaid [1].
Barring a method of prevention or treatment, total costs of
care will grow to an estimated $1 trillion in 2050 [1]. The
high costs of caring for Alzheimer’s and other dementias
make them among the most costly conditions in the United
States [2,3].
Perhaps even more daunting than the costs of care is the
burden on individuals and families. Over time, affected
individuals become completely dependent on others.
Underscoring this, about 15 million unpaid family members
and friends provided over 17 billion hours of unpaid care in
2014 [1]. As more baby boomers reach the age of greater risk
of developing Alzheimer’s, it can be expected that millions
of them will spend their retirement years either living with
the disease or caring for someone who has it.
Recognizing the significance of this growing crisis, the
U.S. Department of Health and Human Services (HHS),
under the auspices of the National Alzheimer’s Project Act
[4] (NAPA), created the National Plan to Address
Alzheimer’s Disease. Released in 2012 [5] and updated
annually [6], the National Plan aims to assist individuals
and families affected by Alzheimer’s and other dementias
by advancing research, enhancing care and support, and
increasing collaboration across federal, state, and tribal
governments.
Among the National Plan’s five goals, two goals
specifically relate to care and support: goal 2, “Enhance
care quality and efficiency” and goal 3, “Expand supports
for people living with Alzheimer’s disease and their
families.” Although the federal government has established
a series of milestones required to meet the National Plan’s
first goal on research [7], which have been reviewed by
independent experts [8], it has yet to establish similar
milestones on care and support. Appendix 2 of the most
recent iteration of the National Plan [6] lists “implementa-
tion milestones”—actions that have been completed or are
currently underway by various federal agencies—across all
five goals of the National Plan. However, these are a listing
of actions that have been completed or are currently
underway and are not analogous to the milestones created
by the National Institutes of Health (NIH) to indicate what
must be accomplished by 2025 to successfully attain the
Plan’s first goal regarding research on prevention and
treatments.
To assist with the establishment of analogous milestones
for goals 2 and 3, the Alzheimer’s Association convened an
expert workgroup to develop recommendations on a compre-
hensive set of milestones and timelines. The workgroup con-
sisted of experts in the fields of clinical care and long-termservices and supports, dementia care and support research,
and public policy. In addition, external advisors, including
representatives from various federal agencies and experts
specializing in the fields of elder justice, dementia care,
and public and private health systems, served as peer re-
viewers on the workgroup’s recommendations, providing
input and making suggestions for improvement.
This report outlines the workgroup’s activities and
recommended milestones for adoption by HHS as part of
the National Plan. Table 1 summarizes milestones to meet
goal 2; Table 2 summarizes milestones to meet goal 3.
Within each table, milestones are listed according to existing
strategies in the National Plan. Except for one recommenda-
tion under goal 3 and discussed below, theworkgroup did not
change the existing strategies but focused instead on
developing milestones for each of the existing strategies.
In the tables, under each of these strategies, milestones are
grouped by sections and include a detailed description of
each milestone, its success criteria and an estimated timeline
tomeet those criteria. Although the number of milestones for
each goal appears extensive (73 milestones under goal 2 and
56 milestones under goal 3), each set of milestones is
comparable in volume to the 86 milestones established to
meet goal 1. They are also indicative of the substantial effort
that the workgroup believes is necessary to achieve goals
2 and 3.2. Key activities
From October to December 2015, the workgroup partici-
pated in four phone meetings and one in-person meeting to
formulate and review the milestones. In addition, select
members of the workgroup also participated in topic-
specific calls on select strategies the workgroup felt required
further discussion. Each workgroup member also provided
input through one-on-one interviews and in written
comments on the numerous drafts of the recommendations.
2.1. Establishing objectives
Goals 2 and 3, and their strategies, had been previously
identified in the National Plan. The workgroup did not seek
to change that existing structure or what had been
previously identified but instead focused on developing
milestones for each of the existing strategies. The work-
group used the milestones established by the NIH for
goal 1 as a guide [7]. That effort sets as milestones all steps
and activities that need to be undertaken by 2025 to reach
the overarching goal. However, unlike for goal 1, the lan-
guage of goals 2 and 3 is fairly general, and the workgroup
believed it needed to begin by more specifically articulat-
ing the 2025 “endpoint” in the areas of care and support.
Thus, more specific objectives were established. For both
goals, the objectives are consistent with the ideal care
and support systems for all individuals with chronic condi-
tions. For goal 2, “Enhance care quality and efficiency,” the
Table 1
Proposed milestones for goal 2
Milestone Implementation detail Success criteria
Strategy 2A: Build a workforce with the skills to provide high-quality care
Milestone section: Build and retain a diverse dementia-capable
workforce with the skills and capacity to provide high-quality care
Identify and set targets for dementia-capable workforce needs
at the state and county level*
Collect data on current dementia-capable workforce capacity and
training needs at a state and county level, project growth in
workforce demand, and estimate future shortages. Dementia-
capable workforce should include primary care physicians,
geriatricians, hospitalists, neurologists, psychiatrists,
psychologists, nurses, social workers, health care administrators,
and related disciplines, including physician assistants, nurse
practitioners, direct-care workers, nursing home workers, and
home health aides. Collect information on current and projected
levels of dementia-capable workforce diversity by location, race,
ethnicity, and sexual orientation and set targets to increase
representation of each underrepresented group over time.
Timeline: Short term
Outline county and state 2025 targets for dementia-capable
workforce needs by setting and provider type, published by 2017
Increase dementia-capable workforce through financial
incentives and competitive income
Create financial incentives (through tuition assistance, loan
forgiveness, housing subsidies, and stipends) and ensure
competitive income to increase the number of health care
providers, including professionals and direct-care workers, who
pursue education and training to become dementia capable,
particularly those who make a commitment to work in
underserved communities or underserved provider settings in
otherwise served communities.
Timeline: Long term
Achieve dementia-capable workforce targets across settings and
providers in 80% of states and counties by 2025
Increase dementia-specific technical education for direct-care
roles
Provide funding for dementia-specific direct-care education for
workforce positions that do not require a 4-year college degree
for: (1) students pursuing education for direct-care roles and (2)
community or technical colleges, high school allied health career
or technical programs, and online courses to provide the
necessary education.
Timeline: Long term
Dementia-capable direct-careworkforce targets met in 80% of states
and counties by 2025
Expand efforts to retain direct-care workforce by building
career pathways with supervisory and administrative support
Consult with national and state groups already devoted to developing
direct-care workforce career pathways and form a coalition of
public-private partnerships to develop and implement career
pathways that provide career ladders for direct-care workers,
offer employers a professional pipeline to aid in job recruitment
and retention and have supervisory and administrative
commitment, especially in for- profit facilities. Link workforce
incentives (financial and not) to tenure in career pathway.
Timeline: Long term
Formal direct-care career pathway established by 2020; dementia-
capable direct-care workforce targets met in 80% of states and
counties by 2025
Increase diverse dementia-capable workforce through financial
incentives
Create financial incentives for health care providers from diverse
communities to pursue dementia-specific practice in those
communities. Focus efforts on diverse groups, including tribal
populations, African Americans, Hispanics, and lesbian, gay,
Incentives in place to increase diversity of the ADRD workforce by
2025
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bisexual, and transgendered (LGBT) individuals, which are
underrepresented in the dementia-capable workforce relative to
the Alzheimer’s disease and related dementias (ADRD)
population. Examinewhether the loss of state and federal benefits
when an individual returns to the workforce creates a barrier to
attracting workers from diverse communities.
Timeline: Long term
Milestone section: Ensure health care providers across settings
are skilled and credentialed in dementia-specific care
Create and gain endorsement of national professional
dementia-specific training curricula tailored to clinical specialties
Create national dementia-specific curricula, incorporating best of
existing programs, for higher education, tailored to primary care,
geriatrics, hospital care, neurology, psychiatry, psychology,
nursing, social work, health care administration, and related
disciplines. The curricula should include how and when to use
cognitive assessments, ADRD progression, communication skills
(with diagnosed individual and key family and friend caregivers),
role of key family and friend caregivers (as part of care team and
caregiver health), care planning in the context of other
comorbidities including postdiagnosis and end of life, daily life
skills for person with ADRD, importance of person-centered care,
challenging behaviors and nonpharmacologic interventions to
address, and medication management. Include training on
identifying the root cause of behavioral expression and
addressing through an individualized approach focusing on the
strengths and preferences of the individual. Incorporate
dementia-specific components into School of Public Health or
other notable curricula for use with undergraduate public health
students. Ensure that cultural competency is a key component of
all curricula. Seek endorsement by key health professional, trade,
and accreditation associations, incorporate curricula components
in relevant educational textbooks, and encourage adoption of
curricula by schools.
Timeline: Short term
National curricula endorsed by key associations tailored to all
relevant providers by 2019; primary care by late 2016; geriatrics
and hospitalists curricula by 2017, health care administration,
social work, and nursing curricula by 2018, neurology,
psychiatry, and psychology curricula by 2019; incorporation into
undergraduate Public Health curricula by 2019.
Provide Centers for Medicare and Medicaid Services (CMS)
Direct Graduate Medical Education (DGME) funds only to
hospitals that incorporate the national dementia-specific curricula
within the broader context of geriatric medicine
Tie Medicare Direct Graduate Medical Education (DGME) funds to
the implementation of the national professional dementia-specific
training curricula, within the broader context of geriatric
medicine, for all medical and residency programs focused on
primary care, geriatrics, hospital care, neurology, psychiatry, and
related disciplines with exceptions granted for non-relevant
specialties such as pediatrics.
Timeline: Short term/Medium term
DGME funds tied to all relevant medical training curricula by 2020;
tied to primary care by 2017; tied to geriatrics and hospitalists
curricula by 2018; tied to neurology psychiatry and psychology
curricula by 2020
Expand dementia specialization in universities Support universities in the development and expansion of dementia-
specific track for residents, physician assistants, nurse
practitioners, and psychology students and raise awareness of
availability of such programs to promote enrollment.
Timeline: Long term
.50% of residency, physician assistant, nurse practitioner, and
professional psychology programs adopted a dementia-specific
medical specialization by 2025
(Continued)
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Table 1. Proposed milestones for goal 2 (Continued)
Milestone Implementation detail Success criteria
Develop and implement dementia-specific continuing
education curricula
Collaborate with professional associations and accrediting bodies,
such as the Accreditation Council for Graduate Medical
Education, to develop and improve competency-based, dementia-
specific continuing education curricula for primary care
physicians, geriatricians, hospitalists, neurologists, psychiatrists,
psychologists, nurses, social workers, nursing home and assisted
living administrators, and other related disciplines. Encourage
uptake by health care continuing education programs.
Timeline: Short term
Dementia-specific continuing education curricula endorsed by key
associations tailored to relevant providers by 2019; primary care
by late 2016; geriatrics and hospitalists by 2017, health care
administration, social work and nursing by 2018, neurology,
psychiatry, and psychology by 2019.
Promote dementia-specific continuing education as condition
of license renewal*
Partner with state licensing boards to promote competency-based,
dementia-specific continuing education as a condition of license
renewal for primary care physicians, geriatricians, hospitalists,
neurologists, psychiatrists, psychologists, nurses, social workers,
nursing home and assisted living administrators, and other related
disciplines, with exceptions granted for nonrelevant specialists,
such as pediatricians.
Timeline: Long term
Integration into at leastw40 state licensing boards by 2023; 50 state
licensing boards by 2025
Require dementia-specific continuing education for all
emergency room health care professionals as a CMS condition of
participation
Require mandatory competency-based dementia-specific continuing
education for all emergency room staff including hospitalists,
specialists, and nurses, as a CMS condition of participation for
hospitals.
Timeline: Long term
Dementia-specific continuing education completion by emergency
room staff integrated as a CMS condition of participation for
hospitals by 2024
Milestone section: Ensure all direct-care workers have proper
training to effectively care for persons with ADRD and support
their key family and friend caregivers in home, community, and
institutional settings
Establish minimal standards for person-centered dementia-
specific training for direct-care workers by provider type and by
setting**
Ensure all home, community, and institutional settings (including
but not limited to home health agencies, adult day care centers,
assisted living facilities, hospitals, and nursing homes) meet
minimum standards for ensuring competency-based, person-
centered dementia-specific training to all direct-care staff,
including supportive therapists (physical, occupational, speech),
on hire and annually thereafter. Develop criteria for evaluating the
quality and evidence base behind trainings provided, including
online based. Provide grants to states and technical assistance to
fund the achievement of these minimum standards. Seek
endorsement by key direct-care worker, trade, and accreditation
associations.
Timeline: Short term
100% of states require demonstrated competency as a condition of
employment as a direct-care worker in home, community-based,
and institutional settings nationally by 2019
Adopt dementia-specific direct-care competency as a quality
measure in Medicare compare
Integrate dementia-specific skills and competency among the direct-
care workforce and facility administrators as a quality measure
for nursing homes and home health services in Medicare
Compare.
Timeline: Medium term
Measured and disseminated in Medicare Compare by 2020
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Provide funding to states for demonstrations in developing,
incentivizing, and implementing direct-care dementia-capable
certifications
Provide federal funding to states for demonstrations to develop
direct-care worker dementia-capable certifications with
competency-based, person-centered evaluation requirements for
long-term care (LTC) facility workforce, personal care attendants,
home health aides, care navigators, hospital workers, and others who
are direct-care workers. Ensure certifications meet minimum
standards for dementia-specific training and require recertification at
specified intervals. Work to incentivize and encourage adoption of
dementia-capable direct-care worker certifications nationwide.
Evaluate the feasibility of making direct-care worker certifications
transferrable across states and creating a national direct-care worker
registry to centralize and track certifications.
Timeline: Medium term
Five state demonstrations in developing certifications for direct-care
workers by 2020; 90% of states with direct-care worker
certifications by 2023
Strategy 2B: Ensure timely and accurate diagnosis
Milestone section: Develop consensus on ADRD prevalence
measurements and report ADRD diagnosis levels
Gather and report ADRD diagnostic data Measure and publicly report data on ADRD diagnostic levels
nationally and by state, released within 6 months of year end. If
feasible, report data on a substate level.
Timeline: Short term
ADRD diagnostic levels publicly reported annually starting in 2017
Develop consensus on ADRD prevalence measurement Develop consensus on how to measure ADRD prevalence at the
population level and its variance across communities to enable
diagnostic rate measurement, with the objective of increasing the
safety and quality outcomes of persons with ADRD.
Timeline: Short term
Consensus on how to measure ADRD prevalence disseminated by
2017
Milestone section: Raise public awareness of ADRD and
encourage detection of cognitive impairment
Support ADRD public awareness campaigns to increase
understanding of ADRD among the public and encourage
cognitive assessments among those at greater risk of ADRD
Provide funding to states and nonprofit advocacy groups to support
multilingual and multicultural public awareness campaigns to
raise awareness and understanding, reduce stigma, and encourage
brain health among the general public, as well as encourage
regular cognitive assessments and raise awareness of the
Medicare Annual Wellness Visit among those at greater risk for
developing ADRD.
Timeline: Short term
80% people above 65 believe that ADRD is not a normal sign of
aging by 2018; 80% of people above 65 are comfortable
discussing memory problems with their health care provider by
2018
Activate faith- and community-based organizations to increase
awareness and understanding of ADRD**
Provide and disseminate ADRD awareness materials, leveraging
existing materials where possible, to faith-based and community-
based organizations to help them reach higher risk populations
within their constituencies. Promote brain health in the context of
overall general health needs. Ensure reach to populations at risk
across all locations, races, ethnicities, sexual orientations, and
socioeconomic classes.
Timeline: Short term
Materials created by 2018; updated and redistributed every 2 years
2020 onward; 80% of faith-based and community-based
organizations using materials in each state by 2025
(Continued)
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Table 1. Proposed milestones for goal 2 (Continued)
Milestone Implementation detail Success criteria
Milestone section: Raise physician awareness on importance
of detection of cognitive impairment and equip physicians to
detect impairment, make an appropriate diagnosis, and properly
disclose information about cognitive status to individuals and
their key family and friend caregivers
Support education campaigns targeted toward all relevant
health care providers on timely detection of cognitive
impairment, including in the Medicare Annual Wellness Visit
Allocate funds to educate primary care physicians, other health
providers, and community workers about the importance of
timely detection of cognitive impairment, applying the
appropriate diagnosis, and disclosing cognitive status to the
patient and their key family and friend caregivers, where they
exist and the patient or the Health Insurance Portability and
Accountability Act (HIPAA) clinical judgment allows. Increase
health care provider awareness and understanding of the
Medicare Annual Wellness Visit and knowledge of validated
cognitive assessment tools, through their local and state
conferences.
Timeline: Short term
.70% of physicians are knowledgeable on the importance of
detection, appropriate diagnosis, and patient disclosure by 2018;
.90% by 2022
Encourage providers to include cognitive conversations and
assessments in annual routine visits for populations at greater risk
for ADRD
Work with professional and trade associations, such as American
Medical Association, American Neurological Association,
American Academy of Family Physicians, American Association
of Geriatric Psychiatry, and others to encourage cognitive
conversations and assessments as a standard part of annual
routine visits or check-ups regarding other conditions, for
populations at greater risk for ADRD, including individuals.65
years and persons with Down Syndrome or other intellectual
disabilities.
Timeline: Short term
Regular cognitive assessments incorporated into professional
guidelines by 2018
Modify reimbursement structure to ensure adequate clinician
time to assess cognitive impairment during visits
Assess and modify the reimbursement structures of CMS, other
insurers and health systems to ensure adequate time for primary
care clinicians to assess, appropriately diagnosis and disclose to
the patient and key family and friend caregivers (where exists and
person with ADRD or HIPAA clinical judgment allows) their
cognitive status, which may require multiple visits.
Timeline: Long term
Reimbursement modified by 2024
Identify practices successful in implementingMedicare Annual
Wellness Visits and evaluate approaches to increase participation,
cognitive assessment tools used, and next steps taken when
impairment is detected
Identify provider practices and organizations that have successfully
implemented the Medicare Annual Wellness Visit above a certain
threshold across the country by analyzing Medicare claims data.
Evaluate methods that these successful providers used for
increasing beneficiary participation, the cognitive assessment
tools they used, and common next steps taken after cognitive
impairment was detected, such as care planning.
Timeline: Medium term
Data collected and published annually, starting in 2020.
Issue CMS sub-regulatory guidance on cognitive assessment
tools to be used in the Medicare Annual Wellness Visit
Issue sub-regulatory guidance to clinical practitioners on the
different cognitive assessment tools that would be most
appropriate to use during the Medicare Annual Wellness Visit.
Sub-regulatory guidance in place by 2020; 80% practitioners report
comfort using specified assessment tools by 2022
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Leverage criteria outlined by the National Institutes of Health,
Alzheimer’s Association, and Gerontological Society of America
working groups.
Timeline: Medium term
Evaluate and develop guidelines for populations more likely to
require specialists to diagnose ADRD
Encourage research to identify guidelines for specified populations,
such as individuals with Lewy body dementia, individuals with
frontotemporal dementia, or persons with younger-onset AD,
who may need a referral to a specialist for ADRD diagnosis and/
or treatment. Reversely, specify other populations with ADRD
who can generally be diagnosed and/or treated by primary care
physicians. Publicly disseminate findings.
Timeline: Medium term
Research performed by 2020; guidelines in place by 2021
Equip and require clinicians to disclose cognitive status to
people with clinically consequential cognitive impairment that
affects their independence in activities of daily living and increase
the proportion of those diagnosed with ADRD, or their caregiver,
who are aware of the diagnosis
Partner with key professional, trade, and accreditation associations
to create, endorse, and disseminate cognitive status disclosure
guidelines to clinicians through local, state, and national health
care professional meetings. Guidelines should require cognitive
status disclosure to all persons with clinically consequential
cognitive impairment as a condition of Medicare or other payer
billing at the time of ADRD diagnosis. Key family and friend
caregivers, where they exist and person with ADRD or HIPAA
clinical judgment allows, should be included in the cognitive
status disclosure conversation. Clinicians should provide
information on capacities affecting independence in activities of
daily living, including traditional IADLs (Instrumental Activities
of Daily Living) and financial and medical decision-making
capacity that shows differing impairment and decline across the
dementia continuum. Disclose cognitive impairment to patient,
irrespective of whether the etiology is neurodegenerative or not
(or not known), and follow-up at regular increments to track
course and identify progression. Furthermore, increase the
proportion of those diagnosed with ADRD, or their key family
and friend caregivers, who are aware of the diagnosis, consistent
with the Centers for Disease Control and Prevention (CDC)
Healthy People 2020 (HP2020) Initiative. Provide a written copy
of the cognitive status and/or ADRD diagnosis to the patient to
ensure clear communication. Ensure follow through on
postdiagnostic next steps (strategy 2C).
Timeline: Medium term
Ensure disclosure guidelines adopted by key professional, trade, and
accreditation associations by 2018; materials incorporated into at
least 20 national and 100 state and local annual conferences by
2020; .38% of persons diagnosed with ADRD or their key
family and friend caregivers are aware of the diagnosis by 2020
(consistent with HP2020); .80% of people diagnosed with
ADRD or their key family and friend caregivers are aware of the
diagnosis by 2025
Incorporate cognitive changes and ADRD diagnostic
information, including documentation of key family and friend
caregivers, into Meaningful Use
Ensure cognitive changes and documentation of any ADRD
diagnosis, including stage and classification of ADRD, care plan,
and name and contact information of key family and friend
caregivers (where exists and person with ADRD or HIPAA
clinical judgment allows), is incorporated into the certified
electronic health record technology to enhance care coordination,
while maintaining privacy and security. Where multiple
caregivers exist, record each in all patient medical records,
denoting one as the primary caregiver.
Timeline: Short term
Incorporated into meaningful use by 2017
(Continued)
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Table 1. Proposed milestones for goal 2 (Continued)
Milestone Implementation detail Success criteria
Record all cognitive changes and ADRD diagnostic
information, including documentation of key family and friend
caregivers in all patient medical records
Ensure that cognitive changes, delirium, and depression be recorded
in all patient medical records. Require documentation of any ADRD
diagnosis in the medical record, including stage and classification of
ADRD, care plan, and name and contact information of key family
and friend caregivers (where exists and person with ADRD or
HIPAA clinical judgment allows). If not equipped to provide a stage
or classification, include referral to a specialist equipped to do so and
follow-up with patient to ensure consultation occurs. Where
multiple caregivers exist, record each in all patient medical records,
denoting one as the primary caregiver. Where lack of medical record
integration across care settings exists, ensure each care provider,
including primary care, specialists, hospitalists, and others,
documents patient’s ADRD diagnosis.
Timeline: Short term
Incorporated in Medicare medical record systems by 2018
Strategy 2C: Educate and support people with Alzheimer’s disease and their families on diagnosis
Milestone section: Standardize and ensure basic information
about ADRD and its management are provided immediately
after an appropriate diagnosis is made
Develop guidelines for provider response to ADRD diagnosis Develop guidelines for minimal immediate next steps for clinician to
take after diagnosing an individual with ADRD, including (1)
inform individuals and their key family and friend caregivers or
health proxy, where exists, of the diagnosis, including stage and
classification; (2) discuss and provide individuals and their key
family and friend caregivers or health proxy, where exists, a
standard set of basic postdiagnosis information about ADRD,
what to expect (including potential behavioral issues and how
caregiving approaches may add to or minimize them), and
treatment options, including the option to participate in clinical
trials; (3) refer individuals and their key family and friend
caregivers or health proxy, where exists, to available resources in
the community, including those that can help provide immediate
triage of needs; (4) for those without key family and friend
caregivers or health proxy, assist individuals in identifying
someone to be included in future visits and document that name
and contact information in the medical record, and encourage the
individual to name a health care and financial proxy; and (5)
develop a care plan to be shared with individuals and their key
family and friend caregivers or health proxy, where exists, and
document this plan in the medical record. Define components of a
comprehensive ADRD care plan, including a form to document
the person with ADRD’s preferences for everyday living.
Incorporate these guidelines into any standards of care developed
(Strategy 2D). Recognize that these guidelines represent
principles for ideal situations, yet clinical judgment will require
adaptation to each patient’s heterogeneous circumstances.
Timeline: Short term
Guidelines developed and disseminated by 2018
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Incorporate set of standard ADRD information into medical
records postdiagnosis
Incorporate ADRD educational materials for patients and key family
and friend caregivers into digital libraries to enable physicians to
store and share information on diagnosis. Where electronic
medical records exist, automate process so that when diagnosis is
recorded in records, physician is automatically prompted to send
information to patient electronically or print to provide a hard
copy.
Timeline: Short term
ADRD postdiagnostic educational materials for clinicians
disseminated broadly and incorporated into medical record
systems by 2017
Milestone section: Ensure access to ADRD care planning
services for every person diagnosed
Reimburse for high-quality care planning immediately after
ADRD diagnosis
Modify reimbursement structure to allow clinicians, hospitalists, or
members of their teams, including nurse practitioners, social
workers, certified counselors, clinical psychologists, or other
health care professionals, to work with persons with ADRD and
their key family and friend caregivers, where exists, to outline an
initial person-centered care plan immediately on diagnosis. Care
plan should include care for person with ADRD in the context of
overall health needs and other comorbidities and address minimal
immediate next steps laid out in provider guidelines. Enforce
quality feedback loops and measurement to ensure high-quality
and effective care planning.
Timeline: Long term
Reimbursement tied to provider guidelines in place by 2020; 80% of
health systems/physician practices have this in place by 2022;
.90% of patients with ADRD receive care planning immediately
after diagnosis by 2025
Educate providers on HIPAA allowances that allow clinician to
meet with key family and friend caregivers of persons with
ADRD independently
Work with professional and trade associations to educate clinicians,
hospitalists, and other members of their teams on current HIPAA
allowances that allow for providers’ discretion in certain
circumstances to meet with key family and friend caregivers of
persons with ADRD independently without he or she being
present, especially as it pertains to topics difficult to discuss in
front of the person with ADRD, such as advanced care planning
and behavioral management. Leverage-existing HIPAA
guidelines to educate clinicians and key family and friend
caregivers.
Timeline: Short term
Education disseminated through institutes of higher learning,
continuing education, and health care professional meetings by
2018
Milestone section: Ensure ADRD self-management education
and skill building for persons with ADRD and their families
across provider networks
Reimburse for ADRD self-management education and skill
building across provider networks
Provide Medicare reimbursement for social workers, certified
counselors, or dementia-qualified health care providers across health
systems, to provide ADRD self-management education and skill
building for people with ADRD and their key family and friend
caregivers, similar to existing Medicare reimbursement for diabetes
self-management educators.
Timeline: Long term
Reimbursement available by 2024
Strategy 2D: Identify high-quality dementia care guidelines and measures across care settings
Milestone section: Identify, standardize, and gain endorsement
of ADRD care guidelines across care settings from initial diagnosis
to end of life that are explicitly tied to outcome measurements
(Continued)
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Table 1. Proposed milestones for goal 2 (Continued)
Milestone Implementation detail Success criteria
Identify, standardize, and gain endorsement of national clinical
ADRD standards of care across care settings
Identify key stakeholders in clinical ADRD care (including
government representatives, key professional and trade
associations, private stakeholders, and nonprofits) to (1)
congregate, review, and vet the conceptual framework put forth
by the National Quality Forum, most recent evidence on high-
quality care, and existing ADRD care guidelines and standards,
(2) outline comprehensive standards of dementia care across each
care setting, including primary and geriatric care, specialties,
hospital care, long term services and support, palliative and
hospice care, and other relevant settings, explicitly tied to process
and clinical outcome measurements. Include protocols around
diagnosis and disclosure (strategy 2B), postdiagnostic care
planning guidelines (Strategy 2C), hospital care for acute
problems (Strategy 2D), care management guidelines across
condition continuum (Strategy 2G), safety policies and measures
(e.g. physical restraint) to avoid inappropriate use, prevention and
management of behavioral complications management
(including environmental design), and provision of long-term
services and supports. Specifically provide guidance on
addressing delirium in the broader context of cognitive
impairment. Encourage inter-professional teaming necessary to
provide high-quality ADRD care. Reconcile dementia guidelines
in the context of other comorbidities to provide comprehensive
guidelines for physicians treating ADRD patients with multiple
chronic conditions.
Timeline: Short term
Publish and d minate translational documents on ADRD
standards o are tailored to all relevant providers and endorsed
by key hea care professional, trade, and accreditation
association y 2019: primary care by late 2016; geriatric and
hospital ca y 2017, LTC by 2018, palliative and hospice care
by 2019, sp ialties (including neurology, psychiatry, and
psychology y 2019
Identify, review, standardize, and test ADRD-specific quality
measures for providers and facilities aligned to ADRD standards
of care, and process and clinical patient/family centered
outcomes
Establish ADRD as a conditionwith specific quality measures across
the continuum of Accountable Care Organizations (ACOs),
managed care plans, long term services and supports, and other
payer/provider networks. Identify, review, standardize, and test
quality measures consistent with standards of care and explicitly
tied to process and clinical patient-centered and family-centered
outcomes, including quality of care, care economics, and patient
satisfactionmeasures. Support current development and testing of
ADRD quality measures through state demonstrations.
Timeline: Medium term
ADRD standa incorporated into relevant quality measures across
payer and p vider networks and publicized by 2022
Align reimbursements and regulations to reflect most up-to-
date ADRD standards of care
Adjust CMS reimbursements and federal regulations to tie directly
to ADRD standards of care. Measure and publicize provider
adherence to standards of care on annual basis.
Timeline: Long term
ADRD standa incorporated into relevant reimbursements and
regulations d first compliance report publicized by 2025
Identify and collect population-level outcome measures for
ADRD care, including health care and LTSS, leveraging
community health needs assessments
Identify key outcome measures to be collected on an ADRD
population basis at the national, state, and county level and
disseminated on an annual basis to track progress in ADRD care.
Ensure measurements cover ADRD process and clinical patient-
Outcome mea ements identified by 2018; begin collection by
2020; disse nate by 2021 and onward
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centered and family-centered outcomes spanning both health care
settings and through long-term services and support (LTSS).
Leverage community health needs assessments to collect and
track data on ADRD populations.
Timeline: Medium term
Convene workgroup or workgroups annually to update ADRD
standards of care
Review new evidence around models of care across settings, refine
standards to reflect the best and most cost-effective practice, and
make recommendations for adjustments to ADRD-specific
quality measures, dementia care reimbursement, and regulations
that reflect updates to standards. Disseminate standards publicly,
partnering with professional and trade associations and institutes
for higher education for greater reach. Identify areas with low
adherence to standards of care and develop recommendations on
how to improve their observance.
Timeline: Long term
Annual meetings held; annual report with updated standards of care
released 2018 onward
Milestone section: Outline ADRD-specific guidelines for
hospital, acute, palliative, and hospice care
Specify the components of dementia-competent hospital care
and encourage adoption
Specify guidelines for dementia-competent hospital care, which
should include guidelines on assessing a hospitalized patient’s
cognitive condition at initial sign of impairment, evidence-based
strategies for communicating with patients with cognitive
impairment, guidance on using protocols to address delirium, and
identifying a root cause of behavioral expression and addressing
through a person-centered, nonpharmacologic approach.
Guidelines should also include discharge guidelines, including
identifying a postdischarge arrangement, establishing follow-up
appointments before discharge, providing discharge instructions
to minimize risk of readmission, and working with patient with
ADRD and key family and friend caregivers, where exists, to
align on medication management. Disseminate information and
partner with universities and health care professional and trade
associations to include in hospitalist training and continuing
education.
Timeline: Medium term
Guidelines created, endorsed by key professional, trade, and
accreditation associations and disseminated by 2017;
Incorporated into 80% of hospitalist education programs and 90%
of continuing education credits for hospitalists by 2020;
Collate existing evidence to identify gaps in knowledge,
practice, and funding for alternative acute care models for persons
with ADRD
Collate existing evidence to identify gaps in knowledge, practice,
and funding mechanisms for alternative support models that
allow persons with ADRD to receive high-quality care for acute
episodic illnesses at their residence, including nursing homes,
assisted living facilities, or their home, as opposed to in a hospital.
Ensure key family and friend caregivers are effectively integrated
in acute care models that provide care in the home. Evaluate
whether effective international models, such as Hospital at Home,
might provide higher quality and more cost-effective care for
patients with ADRD.
Timeline: Medium term
Grant funding provided by 2017; at least 4 alternative acute care
model studies by 2019; recommendations released by 2020
(Continued)
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Table 1. Proposed milestones for goal 2 (Continued)
Milestone Implementation detail Success criteria
Develop components of dementia-competent palliative care for
persons with ADRD
Develop components of dementia-competent palliative care for
persons with ADRD, recognizing that palliation should be
included in all ADRD care throughout the condition trajectory
and leveraging the Institute of Medicine (IOM) recommendations
on palliative care for persons with advanced dementia.
Specifically identify guidelines for those who lack advanced care
plans that document their wishes or key family or friend
caregivers or guardians to represent their wishes. Disseminate
these guidelines broadly in the health and legal system.
Timeline: Short term
Dementia-competent palliative care components developed by 2018
Modify hospice criterion from end of life estimate to disability
severity for persons with ADRD
Modify hospice guidelines to remove 6 months until end of life
prognosis criterion for persons with ADRD to allow those with
severe disabilities and in their end of life stage to receive hospice
support in their preferred setting, regardless of whether their end-
stage dementia allows them to live longer than 6 months.
Disseminate these guidelines broadly in the health and legal
system.
Timeline: Long term
Update hospice guidelines by 2025
Milestone section: Ensure dementia care guidelines are tied to
facility accreditations, licensures, and certifications
Increase dementia capabilities in hospitals and nursing homes
through Joint Commission accreditations and certifications
Ensure Joint Commission accreditations of hospitals and
accreditations and certifications of nursing homes include
dementia-capable criteria informed by the ADRD standards of
care. Ensure differential Medicaid reimbursement for nursing
homes with Joint Commission dementia-specific certification.
Disseminate these differential quality conditions to consumers to
better inform their choice of LTC facility.
Timeline: Medium term
Dementia capability incorporated into Joint Commission hospital
accreditation by 2018; differential reimbursement for Joint
Commission certified nursing homes by 2020
Ensure ADRD care standards incorporated into existing home,
community, and institutional care licensures and certifications*
Incorporate ADRD care standards into requirements for home,
community, and institutional care and integrate into existing state
licensure and certification requirements.
Timeline: Long term
Dementia-capable care requirements integrated into state licensures
or certifications for home, community, and institutional care
facilities in 40 states by 2022; 50 states by 2025
Provide supplementary funding to states to enforce home,
community, and institutional facility dementia-specialized care
claims and advertising
Outline federal standards for home, community, and institutional
care settings to claim or advertise dementia-specialized care.
Provide funding to help states ensure that those advertising
dementia-specialized care capabilities are doing so accurately and
honestly.
Timeline: Long term
Federal dementia-specialized care claim standards in place by 2020,
annual ADRD auditing in place in 40 states by 2022; 50 states by
2025
Strategy 2E: Explore the effectiveness of new models of care for people with Alzheimer’s disease
Milestone section: Identify the state of science in ADRD Care
and Support and develop a research road map to build consensus
around best practices
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Build a coalition of cross-disciplinary experts convened by
appropriate agencies to a research summit on care and support for
persons with ADRD and their key family and friend caregivers
Cross-disciplinary fields should include primary care, geriatrics,
hospitalists, geriatric-psychiatry, psychology, social work,
nursing, supportive therapy (physical, occupational, speech),
administrators and medical directors of nursing homes and
assisted living facilities, medical technology, public health, social
science, quality management, health policy research, and others
relevant to ADRD care and support to:
(1) Review progress on national ADRD standards of care, in
both medical settings and long-term supports and services
(strategy 2D).
(2) Agree on success and effectiveness metrics to measure
ADRD care and support research on key family and friend
caregivers and persons with ADRD, such as cost effective-
ness, health care resource utilization, population-level and
system-level process and clinical outcomes, depression
scales, quality of life, and others.
(3) Identify a typology of community-based pragmatic and
adaptive research methods, including those that promote
statistically sound quality improvement methods on a
population-level and system-level. Outline principles for
building intervention studies applicable and scalable to real-
world populations, including those that are most at risk for
ADRD to be complicated by circumstances or
comorbidities, and designed for feasible and adaptive
implementation in community settings. Include a dictionary
of appropriate research applications.
(4) Review effectiveness of existing intervention research to
date in ADRD care and support in improving health and
functional outcomes for persons with ADRD and their key
family and friend caregivers.
Timeline: Short term
Nominate a governing committee, select working group members,
and organize first summit by mid-2017
Release public report on ADRD care and support evidence-
based interventions
Disseminate a report that identifies best practices in pragmatic and
adaptive evidence-based interventions, including those tied to
statistically sound quality improvements at the population-level
and system-level for both persons with ADRD and their key
family and friend caregivers. Identify current gaps in research to
direct future funding. For interventions leading to quality
improvements, applicable to real-world populations, and feasible
for implementation in community settings, report should outline
next steps to scale them up, including funding requirements and
where possible, who should be funded. Prioritize funding needs to
short- and long-term priorities. Incorporate the output of a summit
into other dissemination and implementation initiatives, such as
the Hartford Change Agents Initiative, to encourage and support
translation and adoption of evidence-based programs.
Timeline: Short term
Completion o port summarizing best practices by year end 2017;
funding an sources allocated to address needs by 2018
(Continued)
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Table 1. Proposed milestones for goal 2 (Continued)
Milestone Implementation detail Success criteria
Convene working group annually to review most current
ADRD care and support research
Review updates to national ADRD standards of care (strategy 2D),
review and refine metrics for success and effectiveness, and
review and refine typology of research approaches and principles
for applicability, feasibility, and adaptability. Review new ADRD
care and support intervention research, update recommendations
for best practices, and refine research road map and translational
efforts to encourage implementation. Identify potential new and
innovative practices that should be researched. Review and report
progress in scaling up evidence-based interventions in
community settings and track quality improvement on population
and system levels.
Timeline: Long term
Annual meetings held; annual report released 2017 onward
Ensure geriatric research on general medical conditions
incorporates persons with ADRD
Ensure general geriatric research on medical conditions not directly
related to ADRD includes persons with cognitive impairment to
enhance clinical applicability. Identify gaps in current geriatric
research areas and outline steps to address.
Timeline: Long term
150 non-AD related geriatric studies including persons with ADRD
by 2025
Milestone section: Provide ADRD Care and Support research
funding directed toward person-centered care and support
interventions, informed by Annual Research Summit
Identify and evaluate quality outcomes and cost effectiveness
of interventions and social services to inform clinical decision
making and social supports
Identify evidence and evaluate care and support interventions for
persons with ADRD and their key family and friend caregivers, to
understand program effect on system process, clinical outcomes,
and cost effectiveness. Leverage findings to inform care decisions
for people with ADRD by condition stage, comorbidities, and
other demographic factors. Explore the feasibility of evaluating
social services provided to persons with ADRD and their
caregivers, such as nutrition, social contact, and respite, for
overall system cost and outcome effects. Use findings to inform
standards of care and make the case for program reimbursement
or funding by mandates such as the Older American Act.
Prioritize research to establish methods that address factors
complicating quality measures, including but not limited to
surrogate responses, interactions with decisions about treatment
and cultural issues.
Timeline: Medium term
Targeted request for applications with earmarked funds established
by 2020
Provide funding for community-based pragmatic and adaptive
research methods in ADRD care and support interventions
Provide direct funding for community-based pragmatic and adaptive
studies on ADRD care and support for both key family and friend
caregivers and persons with ADRD, including those that promote
statistically sound quality improvement on a population and
system level. Prioritize studies that are built for applicability and
scalability to real-world populations, including those that are
Targeted request for applications with earmarked funds established
by 2020
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most at risk for complications of ADRD due to social
circumstances or comorbidities and those designed for feasible
and adaptive implementation in community settings. Include
studies related to behaviors and behavioral management that seek
to identify and address the root causes of behavioral issues,
including use of environmental design and training in
interpersonal care practices, at home and in residential settings
that affect behavior. Include studies that seek to develop
innovative services and service-delivery systems for those who
live in rural areas.
Timeline: Medium term
Provide funding to stimulate and support innovative learning
for new models of care for persons with ADRD
Promote funding for innovative learning organizations and
communities to develop community-based participatory designs
to implement and evaluate new models of care for persons with
ADRD that lead to improved population-level economics and
quality improvements, recognizing the heterogeneity of research
methods. Include research on the role of technology in innovative
supports for persons with ADRD and their caregivers across
settings.
Timeline: Medium term
Targeted request for applications with earmarked funds established
by 2020
Provide funding for ADRD care and support translation studies Fund ADRD care and support translation studies to adapt effective
randomized control trials (RCTs) for pragmatic and adaptive use
in community settings for persons with ADRD and their key
family and friend caregivers.
Timeline: Medium term
Targeted request for applications with earmarked funds established
by 2020
Provide funding for comparative effectiveness studies to
identify most effective supportive ADRD interventions
Promote funding of comparative effectiveness studies to assess
which ADRD supportive interventions are more effective for
different sub-groups of patient-caregiver dyads.
Timeline: Medium term
Targeted request for applications with earmarked funds established
by 2020
Provide funding to roll out ADRD care and support
interventions proven effective and adaptive throughout community
settings
Scale up effective, pragmatic, and adaptive ADRD care and support
interventions in community settings for both persons with ADRD
and their key family and friend caregivers, including those that
promote statistically sound quality improvement on a population-
level and system-level, with the goal of providing the most effective
interventions to the greatest number of persons with ADRD and their
key family and friend caregivers.
Timeline: Long term
80% of people diagnosed with ADRD and 80% of their key family
and friend caregivers report having access to an effective evidence-
based intervention by 2025
Strategy 2F: Ensure that people with Alzheimer’s disease experience safe and effective transitions between care settings and systems
Milestone section: Standardize ADRD patient medical records
and advanced care planning forms to ensure provider access
through care transitions
(Continued)
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Table 1. Proposed milestones for goal 2 (Continued)
Milestone Implementation detail Success criteria
Incorporate ADRD expertise in efforts to standardize medical
records across care settings
Ensure the inclusion of dementia as a key focus area in efforts to
standardize patient medical records across care settings.
Incorporate mechanisms of communication through medical
records between downstream and upstream providers and identify
best approaches for identifying key family and friend caregivers
in electronic medical records.
Timeline: Short term
Inclusion of ADRD as a key focus area for standardized medical
records by 2018
Define components of process for clinicians to discuss end of
life planning and standardize comprehensive end of life planning
forms for persons with ADRD
Define process components for clinicians to discuss end of life
planning with persons with ADRD and their key family and
friends, where relevant. Develop comprehensive standard end of
life planning forms, endorsed by leading patient advocacy and
health care professional and trade associations and require
integration into medical records to follow patients between
transitions, particularly between nursing homes, hospice care
settings, and hospitals. Include medical provider orders as part of
standardized forms for patients with ADRD.
Timeline: Short term
Develop components of process for clinicians to discuss end of life
planning and require standardized form, endorsed by leading
patient advocacy and health care professional and trade
associations by 2018
Milestone section: Ensure people with ADRD and their key
family and friend caregivers are supported by effective transition
models between care settings
Identify, encourage, and incentivize the use of evidence-based
ADRD care transition models
Identify, encourage, and incentivize evidence-based ADRD care
transition models that have been shown to improve system
function and quality by improving hospital to home, community,
and institutional transitions and reducing preventable re-
hospitalizations. Use models that incorporate recommended
dementia-competent hospital guidelines, specifically around
effective transitions (strategy 2D).
Timeline: Medium term
Data collected to show cost and quality effectiveness to managed
care payers and providers by 2020
Define unnecessary and preventable transitions, and minimize
transitions, for persons with ADRD
Develop guidelines to define unnecessary and preventable
transitions between settings, including preventable hospitalizations,
for persons with ADRD, make recommendations to reduce and
minimize transitions, and create a system to collect data and track
progress. Incorporate into tracking of ADRD population level
outcome measurements (Strategy 2D). Align efforts with the CDC
HP2020 initiative.
Timeline: Long term
Guidelines outlined by 2018; recommendations, tracking, and
baseline measures in place by 2019; preventable hospitalizations for
persons with ADRD reduced to 22.8% by 2020 (consistent with
HP2020) and reduced by an additional 20% by 2025; all preventable
transitions reduced from baseline by 30% by 2025
Strategy 2G: Advance coordinated and integrated health and long-term services and supports for individuals living with Alzheimer’s disease
Milestone section: Improve care coordination structures for
persons with ADRD
Reform CMS payment structures to include ADRD in risk
adjustment to account for increased services
Adjust risk reimbursement in managed care models for persons with
ADRD to account for their enhanced care needs and the
Reformed payment structures for persons with ADRD by 2024
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correspondingly more complex coordination of necessary
services to meet those needs.
Timeline: Long term
Provide differential reimbursement for CMS Bundled
Payments for episodes of care experienced by persons with
ADRD
Provide differential reimbursement for Medicare Bundled Payments
for episodes of care experienced by persons with ADRD to
account for enhanced care needs and coordination as a result of
ADRD.
Timeline: Long term
Differential reimbursement for bundled payments for episodes of
care for persons with ADRD by 2024
Develop ADRD care coordination guidelines for case or care
managers for people with ADRD
Strengthen care management for ADRD patients by outlining key
principles necessary to coordinate care for this patient group,
especially between the medical system and long-term services
and supports. Ensure care manager for person with ADRD
manages the patient’s ADRD in the context of other comorbid
conditions, including improving communication across multiple
physicians, providing education on self-management for the
person with ADRD and their key family and friend caregiver,
where exists, and overseeing all aspects of condition
management. Ensure all providers are informed when a patient
transitions between settings.
Timeline: Medium term
Guidelines developed by 2020
Identify and remove barriers to chronic care coordination Identify barriers to practitioners performing chronic care
coordination, outline a comprehensive plan to address and ensure
high-quality delivery through quality assurance and performance
improvement measures.
Timeline: Short term
Barriers identified and plan outlined by 2018; plan to address and
quality measures implementation by 2019
Milestone section: Assess and ensure adequate staffing levels
across care settings
Develop a framework for assessing adequate staffing levels
across care settings that care for persons with ADRD
Develop a framework for assessing adequacy of staffing ratios
(including turnover and retention) tied to outcomes across
relevant health care settings and long-term services and supports
that care for persons with ADRD, recognizing that persons with
ADRD have differing care needs. Document findings.
Timeline: Medium term
Framework of adequate staffing levels by care setting identified by
2020
Allow for sufficient staffing levels across care settings to ensure
quality measures are met for persons with ADRD
Ensure relevant health care settings and long-term services and
supports that care for persons with ADRD has sufficient staffing
levels (taking into account turnover and retention) to ensure that
quality measures are met for persons with ADRD. Ensure staff is
equipped with the requisite ADRD knowledge and skills.
Reimburse for appropriate staff levels.
Timeline: Long term
Reimbursement updated by 2022; implemented in 70% of facilities
in each state by 2025
(Continued)
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Table 1. Proposed milestones for goal 2 (Continued)
Milestone Implementation detail Success criteria
Milestone section: Test creative alternatives for care delivery
and reimbursement that are specifically adapted to the challenges
of ADRD and associated disabilities
Enhance ADRD-specific preparedness of care coordination
models
Develop add-on dementia certification for National Committee for
Quality Assurance (NCQA) Patient-centered Medical Home
Recognition care coordination model.
Timeline: Short term
Incorporate by 2018
Evaluate alternative ADRD care delivery models Collect and report evidence on models of care delivery outside
traditional clinical settings (e.g., home-based primary care and
telehealth) and their unique impact on people with ADRD. Adjust
Medicare reimbursement structure accordingly.
Timeline: Long term
Five alternative models evaluated by 2020; reimbursement reformed
by 2025
Implement home-based primary care* Implement home-based primary care models under Medicaid’s state
plan option.
Timeline: Long term
Implemented by 2024
Milestone section: Provide post-acute support for persons
with ADRD
Provide coverage for post-acute support in the appropriate care
setting for Medicare beneficiaries with ADRD, regardless of length
of hospital stay, and set guidelines to identify the appropriate setting
Ensure that persons with ADRD are covered by Medicare to
transition to a post-acute care setting appropriate to their needs for
some intermittent period of time immediately after an inpatient or
outpatient hospital stay, regardless of the current 3 day length of stay
in the hospital requirement, to prevent an unnecessary hospital re-
admittance. Set guidelines to help identify the appropriate post-
acute setting. Ensure that post-acute services and supports are not
limited for other comorbid conditions due to a person having ADRD.
Timeline: Long term
Medicare reimbursement criteria modified by 2025.
Strategy 2H: Improve care for populations disproportionately affected by Alzheimer’s disease and for populations facing care challenges
Milestone section: Provide for the unique needs of persons with
ADRD disproportionately affected or challenged
Prioritize and fund the Office of the Assistant Secretary for
Planning and Evaluation (ASPE) taskforce recommendations on
persons with ADRD disproportionately affected
Prioritize recommendations made in 2013 ASPE (Office of the
Assistant Secretary for Planning and Evaluation) report on
younger-onset dementia, racial and ethnic minorities, and persons
with Down Syndrome and other intellectual disabilities,
identifying quick wins and longer term goals. Outline timeline
needed to address each recommendation and suggest and provide
funding where needed.
Timeline: Long term
Create timeline with short-term and long-term priorities and related
funding needs by 2018 to meet all recommendations by 2025.
Provide comprehensive brain health and ADRD training and
resources in the context of overall health needs to Federally
Qualified Health Centers (FQHCs), disproportionate share
hospitals, and other public institutions to do proactive outreach
Improve the care of diverse populations with ADRD or at higher risk
of ADRD in FQHCs, disproportionate share hospitals and other
public institutions that tend to serve more diverse communities by
providing training and resources to do proactive outreach around
comprehensive brain health and ADRD care in the context of
Supplemental training and resources provided by 2018
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overall health needs.
Timeline: Short term
Improve awareness and access to clinical trials for those
disproportionately affected
Increase awareness and outreach efforts for ongoing clinical trials to
people with ADRD who have historically been underrepresented,
including ethnically and socioeconomically diverse individuals
and those living in rural areas. Perform outreach to tribal
populations to expand participation in ADRD clinical trials. Raise
awareness and encourage clinical trial enrollment annually
during open enrollment.
Timeline: Long term
.35% of ADRD clinical trial participants are ethnically diverse by
2023; .15% of ADRD clinical trial participants are
socioeconomically diverse by 2023; .4% of clinical trial
participants are LGBT by 2023
Milestone section: Expand medical access to underserved
populations with ADRD through telehealth
Expand and track telehealth Develop guidelines for expanding telehealth to increase people with
ADRD’s access to dementia-competent health professionals,
including for diagnostic services, especially in rural areas.
Disseminate toolkit through partnership with professional and
trade associations and local health agencies. Track telehealth
reach and quality in providing care to people with ADRD.
Timeline: Long term
Toolkit developed by 2018; data tracking metrics measured and
publicized by 2020; 80% of rural communities reached by
dementia-qualified physicians via telehealth by 2025
Modify CMS reimbursement for telehealth Modify telehealth licensure restrictions to allow physician
reimbursement for ADRD telehealth care provided across state
lines. Loosen restrictions on requirements that currently require
telehealth to be received within Medicare certified facilities, to
allow patient to receive telehealth care services within their home.
Timeline: Long term
Modified in 40 states by 2020; Modified in 50 states by 2025
*Indicates milestone is primarily the responsibility of state governments.
**Indicates milestone is a joint federal-state responsibility.
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Table 2
Proposed milestones for goal 3
Milestone Implementation detail Success criteria
Strategy 3A: Ensure receipt of culturally sensitive education, training, support materials
Milestone section: Ensure all persons with Alzheimer’s disease
and related dementias (ADRD) and their key family and friend
caregivers receive culturally competent support regardless of
location, race, ethnicity, sexual orientation, or socioeconomic class
Identify and develop scalable culturally competent and
linguistically appropriate ADRD support resources
Build a coalition of public, private, and nonprofit entities to provide
the resources, including grant funding, educational materials, and
training. Coalitions should identify, and create where needed,
highly scalable culturally competent and linguistically
appropriate, evidence-based healthy aging, brain health, and
ADRD program resources. Target healthy aging and brain health
programs to people at risk of developingADRD in the community
and ADRD-specific programs for people with ADRD and their
key family and friend caregivers. Translate programs into
different languages, tailor materials to be accessible online, by
phone, or in person across a variety of settings, and test
materials to ensure comprehension and effectiveness for target
audiences. Collaborate with Office of Minority Health to ensure
Alzheimers.gov includes these materials.
Timeline: Medium term
.35% programs targeted toward ethnically diverse persons with
ADRD or their key family and friend caregivers by 2020; .15%
targeted toward socioeconomically diverse persons with ADRD
or their key family and friend caregivers by 2020; .4% targeted
toward lesbian, gay, bisexual, and transgendered (LGBT)
individuals with ADRD or their key family and friend caregivers
by 2020; 80% of those at risk of ADRD are educated on healthy
aging and brain health by 2020
Expand outreach to people with ADRD and their key family
and friend caregivers to scale delivery of culturally competent
support programs
Increase participation of culturally diverse populations by investing
in efforts to raise awareness of support programs among these
groups and diversify program delivery to increase access,
including program delivery by native language speakers. Scale
program delivery through online or phone resource portals,
community-based organizations, residential facilities, senior
centers, and other relevant settings. Educate and enlist the faith
community and community health workers as local resources that
can help reach out to and support key family and friend
caregivers.
Timeline: Long term
.90% of key family and friend caregivers/peoplewith ADRD dyads
have access to a community-based education or support program
by 2025
Aggregate information on ADRD-related community services
offered at the national, state, and local level**
Work with private and public partners to produce multilingual and
multicultural information describing the availability and
eligibility criteria for all ADRD-related national, state, local, and
localized private support services, where applicable. Where
needed, provide access to personnel who can assist families with
obtaining this support. Provide this information to clinicians to
include in postdiagnostic care planning for newly diagnosed
individuals and their key family and friend caregivers and make
accessible online.
Timeline: Medium term
Information collected and materials developed by 2018; revisited
biannually starting in 2020 to ensure up-to-date information on
community services
Develop a system for collecting and tracking data on the supply,
use, unmet needs, and outcomes of support services received by
Develop a system for collecting and tracking data on the supply, use,
unmet needs, and outcome on quality and cost of care and support
Data collection system in place and annual results published in at
least 40 states by 2020; 50 states by 2023
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persons with ADRD and their key family and friend caregivers as
a population management tool at the state level**
services available and accessed by all persons with ADRD and
their key family and friend caregivers, where exists, by location,
race, ethnicity, sexual orientation, and socioeconomic class. Use
data collection and tracking system as a population management
tool at the state level for persons with ADRD. Learn from
successful state models and disseminate broadly.
Timeline: Medium term
Strategy 3B: Enable family caregivers to continue to provide care while maintaining their own health and well-being
Milestone section: Provide financial and employer supports
to allow key family and friend caregivers to provide care to
loved ones with ADRD
Provide tax and social security credits for key family and friend
caregivers**
Provide federal/state tax credits or deductions and social security
credits to key family and friend caregivers for providing in-home
care, regardless of whether the caregiver and care recipient reside
in the same home, to dependent (informal designation) relatives
or friends with ADRD.Where primary caregiving responsibilities
for dependent relative or friend with ADRD are shared across
multiple key family and friend caregivers, allow tax credits to be
split proportional to time spent providing care. Ensure
verifications in place to confirm caregiver status to prevent fraud.
Timeline: Long term
Tax and social security credits in place by 2020; 25% of eligible key
family and friend caregivers taking advantage of tax credits by
2025
Expand funding for Cash & Counseling and similar consumer-
directed programs that pay key family and friend caregivers to
provide care*
Expand funding for Cash & Counseling and similar consumer-
directed programs that allow payment to key family and friend
caregivers for care provided to person with ADRD, in place of
paying a professional caregiver when the person with ADRD is
eligible for such Home and Community Based services. Provide
sufficient funding to eliminate waiting lists for these consumer-
directed programs.
Timeline: Medium term
Double funding for consumer-directed programs such as Cash &
Counseling by 2020
Increase funding for National Family Caregiver Support
Program
Improve federal funding to the states as part of the National Family
Caregiver Support Program of the Older Americans Act (OAA
Title III) to ensure key family and friend caregivers of persons
with ADRD are supported in caring for their loved ones at home
as long as needed.
Timeline: Medium term
Double funding for National Caregiver Support Program by 2020
Amend Family and Medical Leave Act (FMLA) and related
state laws**
Expand benefits coverage under FMLA and related state laws for
key family and friend caregivers to include aunts/uncles, siblings,
in-laws, grandparents, and nonrelatives with ADRD.
Timeline: Medium term
Integrate into law by 2020
Support paid family leave to key family and friend caregivers of
people with ADRD**
Investigate the feasibility and work to expand paid or partially paid
family leave for key family and friend caregivers of people with
ADRD to all those currently covered under FMLA or similar state
laws, as well as aunts/uncles, siblings, in-laws, grandparents, and
nonrelatives with ADRD.
Timeline: Long term
Integrate into law by 2025
(Continued)
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Table 2. Proposed milestones for goal 3 (Continued)
Milestone Implementation detail Success criteria
Identify best practices and incentivize employer supports for
key family and friend caregivers of persons with ADRD**
Identify best practices for businesses and other workplace sites to
offer key family and friend caregivers support services such as
flexible work hours, telecommuting, on-site adult day care
services, referrals to community-based support services,
counseling, and others through Employee Assistance Programs
and other employee initiatives and disseminate findings. Provide
incentives to encourage employer uptake of identified best
practices in supports for key family and friend caregivers of
persons with ADRD.
Timeline: Long term
Best practices identified and disseminated by 2017; incentive
programs in place for public employers by 2022; for private sector
by 2025
Milestone section: Facilitate access to supplementary care
supports for persons with ADRD
Expand state assessment to consistently identify key family and
friend caregiver-related needs and coordinate access to evidence-
based programs**
Expand state assessments to consistently identify key family and
friend caregiver-related needs and connect them with the
necessary resources to resolve those needs, through online self-
assessment resources or financial support for in-person
assessments, recognizing that caregiver services and supports are
a key public health initiative. Create a pilot program to provide
assessments for key family and friend caregivers ,65 years and
provide CMS reimbursement for these assessments for key family
and friend caregivers .65 years. Based on identified needs,
connect caregivers with effective, pragmatic, and adaptive
support programs that have been identified to best meet their
specific needs. (See strategy 2E).
Timeline: Medium term
Online resources for assessment in place by 2018; Pilot program in
place for key family and friend caregivers under 65 years by 2020;
CMS reimbursement policy in place for key family and friend
caregivers .65 years by 2020
Help launch volunteer respite programs in local communities** Develop strategies and provide grant funding to help recruit, screen,
train, and launch volunteer respite programs, similar to those
provided for parents of adopted/foster children, through a variety
of sources: nursing and other allied health schools’ intern
programs, volunteer organizations, school volunteer placement
offices, faith-based groups, community organizations, and others.
Provide resources to support self-sustainability after grant funds
run out. Ensure ADRD respite programs are included in
community resource networks for key family and friend
caregivers (Strategy 3A) and provide viable options for persons
with the greatest demonstrated need (e.g., rural areas, tribal
populations).
Timeline: Long term
500 grantees by 2020; At least 25% of those programs sustained
after grant funds run out by 2025
Evaluate state dual eligible demonstrations and recommend
adoption of most successful models
Evaluate Medicare/Medicaid dual eligible beneficiary
demonstrations on integration of care and alignment of financing
and administration for persons with ADRD currently in progress
across various states. Determine their relative cost and quality
effectiveness and recommend the most successful models for
adoption and expansion.
Timeline: Short term
Evaluation and recommendations completed by 2017;
Implementation of successful models by 2019
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Improve Home and Community Based Services (HCBS)
waiver benefits and state plans to expand and improve key family
and friend caregiver support services for those eligible*
Expand HCBS coverage benefits, both through waiver benefits and
state managed care plans, to better meet the needs of persons with
ADRD as the condition progresses and increased home support is
required to keep the person with ADRD living safely at home.
Ensure managed care organizations include statements about
their ability to work with persons with ADRD. Provide sufficient
funding to eliminate waiting lists for these programs.
Timeline: Medium term
Increase funding by 25% per recipient for waiver benefits in at least
40 states for existing recipients by 2021; all 50 states by 2023
Modify short-term, in-home care covered by Medicare to
include intermittent key family and friend caregiver support and
skill building
Allow Medicare to cover key family and friend caregiver support
and tailored skill building at home, by a certified home health
aide, to help them care for the person with ADRD on an
intermittent basis, either during a time of crisis or based on severe
cognitive and functional disability. Provide sufficient funding to
prevent waiting lists for these programs.
Timeline: Long term
Program reimbursed under Medicare by 2025
Milestone section: Ensure key family and friend caregivers
receive proper health care services, including counseling and
mental health care
Identify key family and friend caregivers in their own medical
records and update status regularly
Include notes in key family and friend caregivers’ medical record
that identifies them as a “primary caregiver” similar to other
recorded health behaviors such as exercise levels or alcohol
consumption to ensure their physicians use that information to
assess common issues such as sleep and stress and provide
necessary preventative services to account for their higher health
risks. Ensure designation is updated regularly to maintain
accurate status.
Timeline: Short term
Key family or friend caregiver designation in medical record
systems by 2018
Build evidence-base around health impact of caregiving for
persons with ADRD
Identify and collect existing evidence and provide funding for
research to fill existing gaps in knowledge around the health
impact and risks of caregiving, as well as successful health
interventions for key family and friend caregivers of persons with
ADRD to mitigate those risks. Use evidence base to make
recommendations on improvements to the health system.
Timeline: Medium term
Summary of health impacts of caregiving released by 2020;
recommendations implemented by 2022
Provide proactive outreach to promote health and preventative
services to key family and friend caregivers of persons with
ADRD
Recognize caregiving as a health risk factor that warrants public
health attention. Encourage health professionals to provide
proactive outreach encouraging health assessments for key family
and friend caregivers. Based on identified needs, outline a
comprehensive action plan and referral to support services and
primary care interventions targeted at their high-risk health areas,
such as counseling and mental health care. Refine offerings to
align with the newest evidence base around the health impact of
caregiving.
Timeline: Long term
Health professionals providing health assessments and preventative
services for 50% of key family and friend caregivers by 2025
(Continued)
A
lzh
eim
er’s
A
sso
cia
tion
N
a
tio
n
a
l
P
la
n
C
a
re
a
n
d
S
u
p
p
o
rt
M
ilesto
n
e
W
o
rkg
ro
u
p
/
A
lzh
eim
er’s
&
D
em
en
tia
1
2
(2
0
1
6
)
3
3
4
-3
6
9
3
5
7
Table 2. Proposed milestones for goal 3 (Continued)
Milestone Implementation detail Success criteria
Provide grant funding to organizations to provide support
services for children of parents with younger-onset ADRD
Provide grant funding to community-based, faith-based, nonprofit,
or governmental organizations to build the infrastructure and
facilitate the provisions of support services to children of parents
with younger-onset ADRD, separate from groups targeted at
other conditions.
Timeline: Long term
.90% of chi n of people with younger-onset ADRD have access
to a comm y-based support program by 2025
Strategy 3C: Assist families in planning for future care needs
Milestone section: Disseminate information on care providers
and services to help families make care choices
Create public recognition system to identify home, community,
and institutional-based services based on high-quality ADRD
care*
Create public recognition system to identify home, community, and
institutional-based services based on high-quality ADRD care
and verified dementia-specialized care, tied to state certifications,
licensures, and nursing home Joint Commission accreditations
and certifications (See Strategy 2D), as well as cultural
competency, to help inform consumer choice. Make information
accessible online and update regularly.
Timeline: Long term
Recognition em in place and disseminated publicly by 2020;
40% of ho , community-, and institutional-based providers
enrolled in east 40 states by 2022; 60% enrolled in all 50 states
by 2025
Create a public-private partnership to initiate a system for
identification and consumer review of ADRD qualified
physicians
Create a public-private partnership to outline criteria for identifying
“dementia-qualified” practitioners, which may include some
combination of minimum number of ADRD patients in practice;
board certification in specialties such as neurology, geriatrics,
geriatric psychiatry, or geriatric psychology; minimum ADRD
training programs completed for primary care physicians such as
the Harvard Dementia Care Program or others. Partnership should
provide designation for all practitioners who meet such
requirements as “dementia-qualified” and create a system to
disseminate that list to the public and request consumer reviews
for these physicians, enabling consumer choice based on quality.
Partnership should align on objective rating criteria for reviews
and ensure quality controls in place to verify reviewer
authenticity.
Timeline: Long term
Criteria for “ entia-qualified” outlined and endorsed by leading
profession ssociations by 2018; consumer review forum
launched 020; .80% of “dementia-qualified” physicians
reviewed quality controls in place by 2025
Incorporate ADRD quality care into Medicare Five-Star Rating
systems
Ensure the Five-Star Rating Systems for Medicare Advantage,
prescription drug part D plans, nursing homes, and other care
facilities reflects quality coverage of care and support for persons
with ADRD and their key family and friend caregivers to help
inform patient choice of health payer and provider. Align rating
system’s criteria to quality standards for dementia care (Strategy
2D).
Timeline: Short term
Incorporated 018
Milestone section: Ensure families have the tools and
opportunities to engage in advanced legal, financial, and care
planning
Evaluate and address barriers for persons with ADRD and their
key family and friend caregivers to access and use available care
and support services
Identify existing research completed to date and further evaluate
barriers for persons with ADRD and their key family and friend
caregivers to access and use available ADRD care and support
Report relea n barriers to access and utilization of care and
support se es for persons with ADRD and their caregivers and
recommen ons to reduce by 2018; update released in 2022
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services that could increase the care quality and reduce the cost of
their health care resource utilization. Make recommendations to
reduce those barriers to access.
Timeline: Short term/Medium term
Provide funding and create triggers to encourage greater
participation in advanced care, legal, and financial planning for
persons with ADRD
Provide funding to hospitals/clinics to have nurse practitioners,
social workers, certified counselors, or other nonphysician
facilitators help families complete advance care directives as part
of a care plan on ADRD diagnosis (Strategy 2C). Additionally,
identify specific “trigger” points, such as when one is admitted to
the hospital, fills out a life insurance policy, or signs up for social
security to encourage comprehensive advanced care, legal, and
financial planning, enabling persons with ADRD to make vital
decisions while still cognitively aware. Provide guidance on how
and when to address the conversation around limiting access to
equipment that could endanger public safety as a result of
cognitive impairment, including motor vehicles, guns, and others.
Build a coalition of public, private, and nonprofit entities to
ensure “trigger” points for advanced care directives using
standardized forms (strategy 2F) are implemented into the
appropriate health, legal, and financial systems to be completed
by persons with ADRD and their key family and friend caregivers
before a time of crisis.
Timeline: Long term
Funding provided for facilitators of advanced care planning by 2018;
Trigger points identified by 2019; advanced care, legal, and
financial planning incorporated at trigger points by 2022; .90%
of persons with ADRD completing advanced care directives at or
before trigger points by 2025
Milestone section: Increase access to financial supports to pay
for future care needs
Incentivize employers to offer long-term care (LTC) insurance Incentivize employers to offer LTC insurance policies as part of
common benefit packages, alongside health, life, dental, and
others, to encourage increased uptake by the workforce.
Timeline: Long term
Incentives in place by 2024
Define standards and restructure LTC insurance to enhance
affordability and coverage
Define standards for LTC insurance, including eliminating
exclusions for persons with ADRD, introducing inflation
protection, ensuring policy can be used at most facilities, and
implementing a federal “backstop” for coverage of individuals
with ADRD to constrain the risks being insured, enhancing the
affordability, coverage, and reliability for people in need.
Restructure LTC insurance to meet guidelines.
Timeline: Long term
Standards defined and LTC insurance restructured by 2025
Explore the feasibility of new regulation that allows life
insurance policies to convert to LTC insurance**
Partner with LTC insurance commissioners to explore the feasibility
of new insurance regulations that allow an individual to convert life
insurance to LTC insurance to fund long-term services and supports.
Timeline: Long term
Feasibility investigated by 2023; Regulation enacted by 2025 if
deemed feasible
[Revised] Strategy 3D: Maintain the dignity and rights of people with Alzheimer’s disease
Milestone section: Ensure legal, financial, and social services
are equipped to serve and protect persons with ADRD
Require ADRD training for adult protective services (APS),
LTC ombudsmen, judges, and court personnel*
Require mandatory ADRD-specific competency-based training for
state APS workers, LTC ombudsmen, judges, court personnel,
and others.
Timeline: Long term
70% ADRD-competency rate by 2020; 100% ADRD-competency
rate by 2025
(Continued)
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Table 2. Proposed milestones for goal 3 (Continued)
Milestone Implementation detail Success criteria
Identify quality measures for APS and create a system to collect
data and track performance against those measures
Identify quality standards and measures for APS, such as average
response times to calls, in working with persons with ADRD and
their key family and friend caregivers to measure facility and
worker performance. Create a system to collect data on
performance against quality measures and track progress over
time. Use child protective service system as a model.
Timeline: Short term
Quality standards identified and data collection system created by
2018
Provide federal funding to APS to help facilities ramp up to
meet quality measures and as incentives to maintain high-quality
services
Provide increased overall federal funding to all APS facilities to help
them ramp up service delivery to improve on identified quality
measures over a 3-year horizon. After 3-year ramp up horizon,
continue funding for facilities who meet minimum quality
standards to incentivize high-quality services.
Timeline: Medium term
Increased federal funding for all APS facilities by 2019–2021;
Incentive funding for APS facilities meeting quality standards by
2022
Create a decision support assessment tool for APS workers Develop decision support guidelines and a corresponding easy-to-
use and methodologically sound assessment tool to help APS
workers analyze problems in the field, most common for persons
with ADRD and help them to determine next steps and what, if
any, interventions should be taken.
Timeline: Long term
Guidelines and assessment tool developed by 2020; Used by 80% of
APS workers by 2023; 90% by 2025
Ensure cross-state adult guardianship framework* Ensure Uniform Adult Guardianship and Protective Proceedings
Jurisdiction Act is passed in all 50 states to ensure a framework is
in place for courts in different states to communicate about adult
guardianship cases and thus make the resolution of multistate
jurisdictional issues easier for family members, and in many
cases, alleviate the need for re-adjudication of guardianship
issues.
Timeline: Short term
In place in all 50 states by 2019
Create a public-private partnership to increase access and raise
awareness of legal services equipped to counsel persons with
ADRD and their key family and friend caregivers
Create a public-private partnership that includes key professional
organizations representing attorneys, such as the American Bar
Association, clinician professional organizations, and large
universities to increase access and raise awareness of legal
services in the community, including elder law clinics, to persons
with ADRD and their key family and friend caregivers.
Timeline: Long term
80% of people with ADRD and their key family and friend
caregivers have access and are aware of legal services in their
community by 2025
Provide training on legal guidelines, financial management,
and basic ADRD education, for persons managing the legal and
financial matters of people with ADRD**
Partner with attorneys to incorporate and disseminate educational
materials regarding legal guidelines, financial management, and
basic ADRD knowledge where needed, to conservators,
guardians, power of attorneys, trustees, authorized persons, lay
fiduciaries, and others managing the affairs of people with ADRD
who no longer have the capacity to do so.
Timeline: Long term
Programs and services linked to attorney services by 2022; 80% of
attorney drafting processes include dissemination of legal
guidelines and financial management training by 2025
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Ensure states implement regulations to protect vulnerable
adults from financial abuse resulting from exploitation or
diminished capacity*
Create or strengthen financial industry regulations for bankers,
financial advisers, brokers, investors, and other employees that
manage funds and investments to protect vulnerable adults from
financial exploitation or poor financial decisions due to the
presence of ADRD. Recommendations should include protocols
around identifying potential red flags that indicate suspicious
activity around a person with ADRD’s finances and estate, who to
notify if abuse or diminished capacity is suspected, instances that
require delayed disbursements, mechanisms for contacting APS
or requesting court intervention, and other relevant guidelines.
Timeline: Medium term
Regulations to protect against financial abuse implemented in 40
states by 2020; 50 states by 2022
Require ADRD training for bank employees, financial
advisors, brokers, and investors**
Require bank employees, financial advisors, brokers, and investors
to be trained on state regulations, protocols, and guidelines
designed to protect persons with ADRD from financial abuse.
Timeline: Long term
70% of bank employees, financial advisors, brokers, investors
receive ADRD financial awareness education by 2022; 100% by
2025
Milestone section: Reduce inappropriate use of antipsychotic
and other psychotropic drugs for persons with ADRD in home-,
community-, and institutional-based settings; and address root
causes of behavioral issues
Develop consensus on “inappropriate use” of antipsychotic and
other psychotropic drugs for persons with ADRD
Identify existing guidelines and develop consensus on the definition
of “inappropriate use” of antipsychotic drugs and other
psychotropic drugs among persons with ADRD across care
settings. Use relevant quality improvement methodologies such
as root cause analysis to evaluate the basis for inappropriate use of
such medications, including but not limited to training and
staffing issues, inter-professional dynamics, and weak
accountability systems. Include that antipsychotic and other
psychotropic drugs cannot, and must not, be used to substitute for
high quality, person-centered care.
Timeline: Short term
Consensus developed for “inappropriate use” of antipsychotic and
other psychotropic drugs in persons with ADRD by 2017;
incorporated into ADRD Joint Commission certifications/
accreditations by 2018; baseline set for “inappropriate use”
across settings by 2019
Build on existing efforts to reduce inappropriate use of
antipsychotics and other psychotropic drugs for persons with
ADRD in nursing homes and hospitals**
Align with existing policy initiatives and build on those efforts to
monitor, report, and reduce inappropriate use of antipsychotics
and other psychotropic medications in nursing homes, hospitals,
and the community. Levy financial penalties on facilities that
continue to prescribe antipsychotics and other psychotropic
medications inappropriately.
Timeline: Medium term
Reduce “inappropriate use” antipsychotic and other psychotropic
drug use by 30% from established baseline in nursing home and
hospitalized patients with ADRD nationwide by 2022
Expand outreach to reduce inappropriate use of antipsychotics
and other psychotropic drugs for persons with ADRD across all
care settings**
Expand education and outreach efforts beyond nursing home and
hospital settings to include assisted living facilities and other care
settings.
Timeline: Long term
Reduce “inappropriate use” antipsychotic and other psychotropic
drug use for persons with ADRD across all care settings by 30%
from established baseline by 2024
(Continued)
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Table 2. Proposed milestones for goal 3 (Continued)
Milestone Implementation detail Success criteria
Address root causes of behavioral issues among persons with
ADRD through research and development of measures
Provide funding for research, including translational research,
related to nonpharmacologic methods of preventing care-
disrupting behaviors as well as managing such behaviors when
they occur. Include research to improve understanding the root
causes of such behavior, including factors in both the physical and
interpersonal environments of care. Embed this understanding in
training programs for all care partners (professional and
nonprofessional staff and key family and friend caregivers) aimed
at prevention and mitigation of behavioral complications. Follow
training with methods for measuring and sustaining
improvement, ongoing assessment of treatment implementation,
periodic feedback on care provider performance, and, in health
care and residential settings, adopt a systems approach that
involves all levels of staffing. Develop quality and outcome
measures for various care settings on implementation of best
practices regarding non-pharmacologic alternatives. Monitor
effectiveness of quality and outcome measures, and adjust
measures according to the findings and additional research.
Timeline: Medium term
Targeted request for applications with earmarked funds established
by 2018; quality and outcome measures established by 2020;
measures adjusted based on effectiveness by 2023
Milestone section: Provide funding for community development
and scale up of evidence-based meaningful activities for persons
with ADRD
Provide funding for community development and scale up of
evidence-based meaningful activities for persons with ADRD
Provide grant funding and other resources to help community and
institutional facilities, including adult day care, assisted living,
nursing homes, and others, develop and scale-up innovative and
low-cost evidence-based purposeful living activities for
individuals with cognitive impairment that will also provide
respite for key family and friend caregivers. Establish meaningful
activities across the care continuum that are specifically adapted
for the person with ADRD, including vocational, rehabilitative,
social, and recreational activities and the use of memory/
communication books in nursing homes. Provide resources to
support self-sustainability after grant funds run out. Ensure
ADRD meaningful activity programs are included in online and
community-based key family and friend caregiver support
resource locator services and provide viable options for persons
not presently served, such as tribal groups and persons with
ADRD in rural areas.
Timeline: Long term
500 grantees by 2020; 200 of those programs sustained after grant
funding runs out by 2025
Strategy 3E: Assess and address the housing needs of people with Alzheimer’s disease
Milestone section: Adapt community and institutional care
settings and payment methods to better meet the unique needs
of persons with ADRD and their key family and friend caregivers
Provide funding to evaluate alternative long term care models,
including for specific populations
Provide funding for pilot programs to evaluate alternative long term
care models and care settings that may be more or less effective
Funding for pilot programs available by 2020; evaluations of pilot
program effectiveness by 2022
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for different populations. Ensure programs for persons with
younger-onset ADRDwho have unique care needs and those with
related dementias, who can be refused by some community and
institutional settings, are specifically evaluated. Models that may
be considered for evaluation include continuing care retirement
centers, the Green House Model, adult foster care, group homes,
housing options that include the person’s spouse without ADRD,
and other models that may enhance quality and cost effectiveness.
Timeline: Medium term
Provide state specialty housing vouchers for low-income
persons with ADRD*
Provide specialty housing vouchers that expand housing options for
low-income persons with ADRD beyond institutional settings
allowing use in a variety of community care settings, including
assisted living and other residential care facilities.
Timeline: Long term
Flexible voucher system for residential care in 40 states by 2024; 50
states by 2025
Promote use of universal design in facilities and products
targeted at older adults
Partner with architectural, design, and engineering schools to
promote the use of universal design in building architecture and
products designed for older adults at greater risk of cognitive
impairment, such as nursing homes, assisted living facilities,
adult day centers, senior centers, and other retirement
communities.
Timeline: Long term
Universal design integrated in 80% of institutional and community-
based settings by 2025
Milestone section: Support home care for persons with ADRD
by providing financial and professional supports for key family
and friend caregivers to make care at home sustainable
Provide standard assessment guidelines and/or tools to help
determine most suitable housing arrangements for persons with
ADRD**
Assess an individual with ADRD’s functional needs and key family
and friend caregivers’ input to determine the least restrictive
environment that they can safely live in. Make assessment tool
available online and work with health care professional and trade
associations to disseminate to clinicians and care coordinators to
help facilitate a person-centered conversation around housing
arrangements for a person with ADRD.
Timeline: Short term
Assessment tool in place by 2018
Provide guidelines that will enhance the safety of persons with
ADRD remaining in their home as condition progresses,
incorporating technology where relevant
Collaborate with health care professionals, including hospitalists,
home health care professionals, and legal professionals to develop
guidelines to permit persons with ADRD to safely remain in their
current living environment, including interventions, based on the
growing number of evidence-based models of care to support
people with dementia at home, to reduce risks of fall, wandering,
and poor nutrition. This would include providing safety checklists
to key family and friend caregivers and conducting home
assessments to ensure the safety of the living environment.
Recommendations should be made to improve any problem areas
flagged in the assessment, including the incorporation of
technological solutions where relevant.
Timeline: Short term
Home care guidelines endorsed by key stakeholder and advocacy
groups by 2018
(Continued)
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Table 2. Proposed milestones for goal 3 (Continued)
Milestone Implementation detail Success criteria
Provide grants to develop programs to meet the needs of
persons with ADRD who live alone
Develop a grant program for local or state entities to provide funds to
better understand the prevalence and unique needs of people with
ADRDwho live alone and to develop programs to meet those needs,
including care support when a person with ADRD living alone
transitions out of a hospital or skilled nursing facility.
Timeline: Medium term
Grant funding provided to 200 communities by 2020
[New] Strategy 3F: Support communities that are inclusive and safe for persons with Alzheimer’s disease and related dementias
Milestone section: Ensure persons with ADRD are safe and
cared for in emergency situations
Implement missing person protocol for adults with ADRD* Ensure law enforcement agencies implement a missing persons
protocol for adults with ADRD in all 50 states.
Timeline: Medium term
All 50 states have adopted a Missing Persons protocol by 2020
Require ADRD training for first responders* Require mandatory ADRD-specific competency-based training to
first responders, including law enforcement, fire fighters,
paramedics, EMTs, and others about medical and behavioral
issues related to ADRD so they are prepared when responding to
an emergency involving these individuals. Identify or develop
training guidelines for these groups. Ensure law enforcement
training includes Missing Person protocols for adults with
cognitive impairment.
Timeline: Short term
70% ADRD-competency rate of first responders by 2018; 100%
ADRD-competency rate by 2020
Identify or develop guidelines for identifying elder abuse or
neglect in patients with ADRD
Identify guidelines for health care providers to identify potential
elder abuse in patients with ADRD in hospital emergency rooms,
primary care settings, and first response situations and outline
appropriate follow-up.
Timeline: Medium term
Incorporated into Joint Commission hospital accreditation
requirements, first-responder training, and ADRD standards of
care by 2020
Convene a public-private group to identify and standardize
emergency intervention health system protocols for persons with
ADRD
Convene key public and private stakeholders to identify guidelines
and outline protocols for health systems and law enforcement
agencies when the following occur: (1) a primary family or friend
caregiver is admitted to the hospital and there is no one else to
care for the person with ADRD; (2) a primary family or friend
caregiver passes away and there is no one readily available to care
for the person with ADRD. Incorporate into state emergency
preparedness plans, including natural and man-made disasters.
Timeline: Medium term
Emergency interventions in place nationally by 2020
Identify and standardize emergency intervention protocols for
persons with ADRD*
Implement emergency intervention in care facilities, hospitals, and
the broader community for when the following occur: (1) a person
with ADRD is found by public safety workers alone and in need
of additional care and there is no one to provide care or time is
needed in a court system to complete guardianship procedures;
and (2) person with ADRD is found by Adult Protective Services
to be in a dangerous situation. Incorporate into state emergency
preparedness plans, including natural and man-made disasters.
Timeline: Short term
Emergency interventions in place in 40 states by 2018; all 50 states
by 2019
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Milestone section: Ensure local community members who
come in contact with persons with ADRD receive basic-dementia
training
Create “dementia-sensitive” community-based qualification
system
Outline federal guidelines for “dementia-sensitive” qualification,
including cultural competency, of public and private community
entities and businesses, such as movie theaters, restaurants,
hotels, and other locations. Provide funding to create public and
corporate awareness of the importance of dementia sensitivity
and the unique needs of those with ADRD who live alone.
Timeline: Long term
Guidelines in place by 2017; 300 dementia-qualified businesses with
over 50 employees by 2020; 1000 by 2025
Provide ADRD training for local governmental officials* Provide basic ADRD education for Area Agency on Aging (AAA)
employees, postal workers, transportation employees, and other
community-based workers on how to interact with individuals
with ADRD.
Timeline: Long term
70% of AAA employees, U.S. postal workers, transportation
employees have basic ADRD education by 2020; 100% by 2025
Milestone section: Ensure safe transportation options for
persons with ADRD
Fund public and social service transportation programs for
persons with ADRD**
Provide additional funding for accessible and affordable
transportation services that are dementia capable and improve the
coordination of public and social service transportation. Offer
incentives and training to local nonprofits to launch volunteer
transportation programs in local communities. Give priority to
providers familiar with this population, such as senior centers,
faith-based programs, and adult day programs.
Timeline: Long term
40% of top 50 metropolitan areas have dementia-capable public
transportation systems (where applicable) and/or community-
based volunteer transportation programs by 2025
Provide referrals to community agencies for individuals with
ADRD who no longer have driving privileges*
Ensure sufficient capacity in local communities and provide
Department of Motor Vehicles, Secretary of State, and other
relevant vehicle regulation agencies the necessary information to
refer persons with ADRD to social and community agencies for
assistance with transportation needs in the case of voluntary or
involuntary surrender, expiration, or loss of driving privileges.
Timeline: Long term
Referral program incorporated into 40 states by 2024; 50 states by
2025
*Indicates milestone is primarily the responsibility of state governments.
**Indicates milestone is a joint federal-state responsibility.
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Alzheimer’s Association National Plan Care and Support Milestone Workgroup / Alzheimer’s & Dementia 12 (2016) 334-369366workgroup developed the objective: All persons living with
Alzheimer’s disease and related dementias, regardless of
location, race, ethnicity, sexual orientation, or socioeco-
nomic class, should receive high-quality person/family-
centered care by well-trained practitioners and workers
from detection and diagnosis through end-of-life, across all
health care and long-term services and supports settings
and systems. For goal 3, “Expand supports for people living
with Alzheimer’s disease and their families,” the workgroup
developed the objective: People with Alzheimer’s disease
and related dementias, their families, and their caregivers
should have access to effective interventions and supports
that expand their care giving skill sets, enhance the meaning-
fulness and quality of their lives, and reduce the burden of
Alzheimer’s disease and related dementias.2.2. Building on existing efforts
The workgroup acknowledged ongoing efforts of key
federal agencies toward the established goals and strategies
in the National Plan. In addition to noting areas where ma-
terial progress had been made—such as the dementia-
specific primary care curriculum under development by
the Health Resources and Services Administration; the
Centers for Disease Control and Prevention’s (CDC)
Healthy People 2020 dementia objectives; the Administra-
tion on Community Living’s work in support of caregivers,
including the Alzheimer’s Disease Supportive Services
Program and the creation of alzheimers.gov; and the Cen-
ters for Medicare and Medicaid Services’ (CMS) efforts to
support the detection of cognitive impairment during the
Medicare Annual Wellness Visit—the workgroup sought
to incorporate and expand on these efforts in its
recommendations. In addition, the workgroup noted that
in areas of common subject matter, the recommended
milestones are consistent with the CMS Quality Strategy
report [9].2.3. Defining terms
The workgroup noted different interpretations for various
terms used in NAPA, the National Plan and general
Alzheimer’s lexicon and sought to establish terms that
were more explicit and inclusive. For example, although
the workgroup acknowledged that NAPA and the National
Plan explicitly use the term “Alzheimer’s disease” to
encompass all forms of dementia, the workgroup chose to
adopt “Alzheimer’s disease and related dementias,” abbrevi-
ated ADRD, throughout the milestones.
Similarly, the workgroup believed that terms like
“families” or “family caregivers” were not inclusive of un-
paid assistance provided by individuals who are unrelated
to their care recipients. Therefore, as theworkgroup believed
that these unrelated, unpaid caregivers were nevertheless
meant to be included as beneficiaries of the supportsreferred to in the National Plan—and often provide crucial
support—theworkgroup chose to adopt the term, “key family
and friend caregivers.” Although paid caregivers are not
included in this designation,milestones addressing paid care-
givers are included in the strategy on the workforce, consis-
tent with the structure and approach of the National Plan.
Furthermore, while using the term “caregivers” is consistent
with thewidely used lexicon, particularly in professional cir-
cles, theworkgroup recognized that the termmay not be simi-
larly used among those family members and friends who are
actually providing care.
Because the workgroup did not seek to amend the already
existing strategies, the recommended use of “ADRD” and
“key family and friend caregivers” is not reflected in the stra-
tegies in the Tables. However, the workgroup recommended
incorporating these amended terms throughout the National
Plan. For example, strategy 2C “Educate and support people
with Alzheimer’s disease and their families on diagnosis”
could be broadened to also include ADRD and key family
and friend caregivers. Likewise, key family and friend
caregivers could be used in place of “family caregivers” in
strategy 3B. Similar changes could be made to strategies
2E, 2F, 2G, 2H, 3C, 3D, and 3E.
The workgroup also spent time discussing the term
“dementia-capable”—what it meant and how it differed
from similar sounding terms such as “dementia-friendly.”
Within strategy 2A, the workgroup agreed the term
“dementia-capable” should be used to describe the target
skill level of the workforce caring for people with
ADRD, but recognized that the term is multidimensional
and that the agreed-on definition may be a limitation of
this work.
The workgroup struggled to come to consensus on what
populations were “disproportionately affected” by Alz-
heimer’s disease and related dementias. Ultimately, the
workgroup adopted the National Plan’s definition, which
identified three specific populations: persons with younger-
onset dementia, racial and ethnic minorities, and persons
with Down syndrome and other pre-existing intellectual dis-
abilities. However, the workgroup believed that other spe-
cific subpopulations are underserved and present unique
challenges beyond the challenges of ADRD in general. As
noted in various milestones (e.g. milestones under strategies
2E, 2H, 3B, 3D, 3E, and 3F) of particular concern are indi-
viduals with ADRD who live alone and/or in rural areas.
Viable service options and research and development on
innovative service-delivery systems are needed for these
populations.
The workgroup experienced similar challenges when in-
terpreting what comprised an “accurate” diagnosis, as
noted in strategy 2B, “Ensure timely and accurate
diagnosis.” The workgroup agreed the word “accurate”
was imprecise, owing to current limitations of diagnostic
tests and cognitive assessment for ADRD and suggested
replacing it with the term “appropriate.” It is possible,
Alzheimer’s Association National Plan Care and Support Milestone Workgroup / Alzheimer’s & Dementia 12 (2016) 334-369 367however, that by 2025—the period covered by NAPA and
these recommended milestones—technological and other
advancements could occur that would add more precision
to the term “accurate.”
2.4. Recognizing the roles of federal and stategovernments
As noted in the National Plan, the workgroup
acknowledged that achievement of an ideal system of care
and support by 2025 will require coordination across federal,
state, and local entities—and, in some cases, by both health
care and non–health care agencies. As a result, the
workgroup recognized that certain of its recommended
milestones would require efforts by both federal and state
governments or would need to be largely addressed
and accomplished at the state level. In Tables 1 and 2,
milestones are assumed to be the responsibility of
the federal government unless denoted with an asterisk
(*), indicating primarily state-level initiatives or two
asterisks (**), indicating joint federal-led and state-led
policies.
2.5. Estimating timelines
The workgroup provided guidance on the estimated
amount of time required to achieve each milestone’s suc-
cess criteria. Milestones that should be expected to reach
their success criteria between today and 2019 are desig-
nated as “short term;” between 2020 and 2023 as “medium
term;” and between 2024 and 2025 as “long term.” The
workgroup recognized that select milestones, such as those
that require changes in regulations or statutes, may take
longer to enact than others. However, with the rapid growth
of an aging population, the workgroup stressed the urgent
need to move forward with milestone implementation. In
other words, the timeline designation should be interpreted
as the recommended date of achievement, not the time-
frame in which to begin addressing the milestones; the
work related to many milestones designated “long term”
must nonetheless begin immediately. Also, the timeline
designation is not meant by the workgroup and should
not be interpreted as reflecting relative importance of the
milestones.
Furthermore, the workgroup noted that not all the mile-
stones are linear in nature. Although it is tempting to think
of milestones in the abstract as a sequential series of ac-
tions or intermediate targets on the way toward meeting
an overarching goal—one action to follow another—that
is neither possible nor always advisable in this case.
Some of the recommended milestones do naturally follow
other milestones. For example, ensuring that quality care
standards are adopted and incorporated in practice settings
necessarily first requires that quality care standards be
established. But, as with the milestones established by
the NIH for goal 1, not all steps that need to be taken
necessarily need to follow specific earlier actions.Numerous milestones can and need to be addressed simul-
taneously, and some milestones will naturally take longer
to achieve given that they involve more complicated legis-
lative and regulatory processes.3. Discussion of specific milestones
Tables 1 and 2 contain all the recommended milestones
for goals 2 and 3 of the National Plan, including detail on
the implementation of each milestone, most of which is
self-explanatory. For a few strategies and milestones,
however, the workgroup believed that it was necessary to
make some specific clarifying comments.
3.1. Strategy 2B on diagnosis
During its discussion, the workgroup deliberated what
was the best way to “ensure timely and accurate diagnosis”
as noted by strategy 2B. Rather than focus on milestones
that solely supported diagnosis of ADRD, the workgroup
felt it was important to also consider milestones that would
support the identification and disclosure of cognitive change
over time. Consequently, theworkgroup concluded that clini-
cians should assess the cognitive and functional skills of in-
dividuals at risk for ADRD and disclose clinically
consequential cognitive impairment—that is, cognitive
impairment that is accompanied by deficits in an individual’s
activities of daily living or instrumental activities of daily
living. Furthermore, clinicians should ensure that diagnosed
individuals and their key family and friend caregivers, where
they exist, are aware of anyADRDdiagnosis. Theworkgroup
clarified that it is not the aim of the diagnosis-related mile-
stone recommendations, given the current state of the sci-
ence, to call for, at this time, the use of biomarkers for all
individuals at risk of cognitive impairment.
3.2. Strategy 2D on guidelines
Themilestones in Strategy 2D include the development of
high-quality guidelines and measures on the clinical care of
individuals with dementia across care settings. Although
mentioned within the recommendations themselves, the
workgroup wanted to underscore that all such quality mea-
sures should be explicitly tied to both processes and clinical
person-centered and family-centered outcomes.
3.3. Strategy 2E regarding research on care and support
practices
The workgroup spent considerable time discussing
milestones to support research on new models of care for
people with ADRD and their key family and friend
caregivers (strategy 2E). The workgroup strongly supported
additional research. But, although the workgroup endorsed
the “gold standard” of randomized-controlled trials
(RCTs) in studies of discrete biochemical interventions
Alzheimer’s Association National Plan Care and Support Milestone Workgroup / Alzheimer’s & Dementia 12 (2016) 334-369368(such as medications), it also noted that evaluating certain
care and support models in RCTs is not always feasible
and may be a poor method of learning from and monitoring
complex, real-world system change. Methods drawn from
management science and epidemiology will often be
more appropriate and should be prioritized and funded in
those settings. There was also consensus on the need to
test innovations and use researchmethods that promote qual-
ity care for all affected by ADRD at a population level, not
just for the individual with ADRD. It should become
possible to compare quality over time in a particular city
or county and to compare across geographical areas.
During discussion on the success criteria, the workgroup
highlighted that some studies may address more than one
milestone, such as translational studies that also evaluate
cost effectiveness of a particular intervention, reducing
the potential number of overall studies needed. The work-
group also noted that a particular care or support
intervention may require multiple replications in separate
studies to be considered evidence based. The workgroup
further noted that variations in treatment and support across
populations of interest would be expected to affect many
measures of quality, either directly or by altering the
proportion of persons living at different stages of ADRD.
Methods should be developed to monitor and account for
these variations.3.4. Strategy 3D on safety, dignity, and inclusive
communities
The workgroup made several observations as it devel-
oped milestones for Strategy 3D, “Maintain the dignity,
safety, and rights of people with Alzheimer’s disease.”
First, the workgroup felt the existing strategy was far
reaching and encompassed too many topics under the
rubric of a single strategy. The workgroup also noted
that, although it is implicit in some of the recommended
milestones on safety (such as recommendations on emer-
gency preparedness and transportation), the idea of
creating and expanding communities inclusive of people
with ADRD appeared to be missing and did not naturally
fall under any specific existing strategy. As a result, the
workgroup recommended revising strategy 3D to focus
on the dignity and rights of people with ADRD and rec-
ommended a new strategy, 3F, “Identify and support ef-
forts to build communities that are more inclusive and
safe for persons with ADRD.” The workgroup agreed
the term “inclusive” was meant to describe the aspiration
of communities effectively adapting to the needs of per-
sons with ADRD, yet recognized the lack of an agreed-
upon consensus of what such an effort entails, thus poten-
tially limiting the work.
Within the realm of dignity and rights for the ADRD
population, the workgroup also noted the inherent ambigu-
ity of safety and risk assessments for persons with ADRD.
The workgroup suggested an overarching commitment toensure reasonable autonomy for persons with ADRD,
recognizing that bearing responsibility for decision making
differs by decision. For example, the choice of what
clothing to wear could be respected for many persons
with cognitive impairment who could not otherwise bear
the responsibility for deciding whether to have an invasive
surgery.
4. Conclusion
Although much work needs to be done to achieve goals 2
and 3 of the National Plan by 2025, the workgroup believed
that the recommended milestones included in Tables 1 and 2
are a significant step toward changing how care and supports
are provided for people affected by ADRD, their families,
and their key family and friend caregivers.RESEARCH IN CONTEXT
1. Systematic review: Pubmed and other searches were
conducted to identify best practices in the care of in-
dividuals with Alzheimer’s and the support of unpaid
caregivers. Published state Alzheimer’s plans and de-
mentia plans from other countries were mined for
policy ideas.
2. Interpretation: For the first time, a set of comprehen-
sive milestones have been identified to achieve goals
2 (care) and 3 (support) of the U.S. national Alz-
heimer’s plan—providing a comprehensive listing
of what is needed by 2025 to ensure a high-quality
care and support system for people with Alz-
heimer’s and their families.
3. Future directions: The milestones could be improved
with the development of a consensus in the field as to
what is meant by “dementia-capable” and what spe-
cifically is needed for communities to be “inclusive”
of individuals with dementia. The milestones could
be strengthened with further research that results in
identification of ways to prevent Alzheimer’s and
of biomarkers that aid in diagnosis.
References
[1] Alzheimer’s Association. 2015 Alzheimer’s disease facts and figures.
Alzheimers Dement 2015;11:332–84.
[2] Hurd MD, Martorell P, Delavande A, Mullen KJ, Langa KM. Monetary
costs of dementia in the United States. N Engl J Med 2013;
368:1326–34.
[3] Kelley AS,McGarry K, Gorges R, Skinner JS. The burden of health care
costs for patients with dementia in the last 5 years of life. Ann Intern
Med 2015;163:729–36.
[4] P.L. 111–375.
Alzheimer’s Association National Plan Care and Support Milestone Workgroup / Alzheimer’s & Dementia 12 (2016) 334-369 369[5] U.S. Department of Health and Human Services. National
plan to address Alzheimer’s disease. Available at: https://aspe.
hhs.gov/national-plan-address-alzheimer%E2%80%99s-disease;
2012. Accessed December 28, 2015.
[6] U.S.Department ofHealth andHumanServices.National plan to address
Alzheimer’s disease: 2015 Update. Available at: https://aspe.hhs.gov/
national-plan-address-alzheimer%E2%80%99s-disease-2015-update.
Accessed on December 28, 2015.
[7] National Institutes of Health. Alzheimer’s disease research implemen-
tation milestones 2013-2025. Available at: https://www.nia.nih.gov/budget-files/alzheimers-disease-research-implementation-milesto
nes-2013-2025.pdf; 2015. Accessed December 28, 2015.
[8] Alzheimer’s Association National Plan Milestone Workgroup
Fargo KN, Aisen P, Albert M, Au R, Corrada MM, DeKosky S, et al.
2014 Report on the Milestones for the US National Plan to address
Alzheimer’s Disease. Alzheimers Dement 2014;10:S430–52.
[9] Centers for Medicare and Medicaid Services. CMS Quality
Strategy 2016. Available at: https://www.cms.gov/Medicare/Quality-
Initiatives-Patient-Assessment-Instruments/QualityInitiativesGenInfo/
Downloads/CMS-Quality-Strategy.pdf. Accessed January 13, 2016.
